4//SEC Filing
Santos da Silva Jorge 4
Accession 0001013762-23-001297
CIK 0001821586other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 7:28 PM ET
Size
16.3 KB
Accession
0001013762-23-001297
Insider Transaction Report
Form 4
Santos da Silva Jorge
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Class C ordinary shares, par value $0.0001 per share
2023-10-01−140,071→ 217,374 total - Conversion
Class A ordinary shares, par value $0.0001 per share
2023-10-01+3,027,483→ 3,027,483 total - Disposition to Issuer
Class C ordinary shares, par value $0.0001 per share
2023-10-01−3,027,483→ 0 total - Conversion
Class A ordinary shares, par value $0.0001 per share
2023-10-01+140,071→ 3,167,554 total - Conversion
Common shares, par value CHF 0.10 per share, of MoonLake AG
2023-10-01−90,000→ 0 total→ Class A ordinary shares, par value $0.0001 per share (3,027,483 underlying) - Conversion
Common shares, par value CHF 0.10 per share, of MoonLake AG
2023-10-01−4,164→ 5,836 total→ Class A ordinary shares, par value $0.0001 per share (140,071 underlying)
Footnotes (4)
- [F1]On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.
- [F2]The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.
- [F3]10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest.
- [F4](continued from footnote 4) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.
Documents
Issuer
MoonLake Immunotherapeutics
CIK 0001821586
Entity typeother
Related Parties
1- filerCIK 0001920509
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 7:28 PM ET
- Size
- 16.3 KB